First-Line Use of Novel Hormonal Agents in Prostate Cancer: A Critical Appraisal

  Abstract: Castration has been the hallmark of the treatment of advanced prostate cancer for nearly a century. Conventional surgical or medical castration for the management […]

Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced Prostate Cancer

H&O How common is resistance to abiraterone and enzalutamide in castration-resistant prostate cancer (CRPC)? ESA Approximately 15% to 25% of patients with CRPC do not respond to […]